YOUR PASS TO SAVE ON THE ONLY 6-MONTH* CGM

PAYMENT ASSISTANCE & SIMPLE SAVINGS

The EVERSENSE® PASS program can help make the EVERSENSE® E3 Continuous Glucose Monitoring System more affordable for you – now and in the future!

THE PASS PROGRAM PROVIDES SUPPORT FOR PATIENTS’ FIRST YEAR — AND BEYOND

 $99*
FOR YOUR FIRST
SENSOR/TRANSMITTER,
AND SECOND SENSOR


INTRO OFFER

Available the first full year. Eligible
patients can experience EVERSENSE E3
CGM for only $99 for initial sensor
and transmitter, and $99 for the
second sensor.

$600
MAX OUT-OF-POCKET FOR
FUTURE SENSORS/TRANSMITTERS


ONGOING OFFER

After the first full year on
Eversense E3, out-of-pocket expenses
are not to exceed $600 for the
patient’s next sensor or sensor/
transmitter combination and may
be less depending on the patient’s
insurance plan.


Offers do not apply to the insertion and removal procedures.
 

ELIGIBILITY OVERVIEW


“INTRO" AND “ONGOING” OFFERS

  • ELIGIBILITY: To be eligible, you must be new to Eversense E3 and have a commercial insurance plan with or without coverage for EVERSENSE® E3.
  • EXCLUSIONS: Government insurance and insurance plans that require purchase directly from HCPs



Get in touch to learn more about getting started on Eversense E3

Please complete your contact details and an Ascensia Diabetes Care representative will follow up with you shortly.


*Field is required

* Up to 6 months.
† The offers above only apply to the cost of the sensor and transmitter or sensor only. They do not cover the cost of the insertion procedure. Limitations and Restrictions may apply. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice. The program benefit is capped per transaction. There may be instances in which patient out-of-pocket costs exceed what is detailed in INTRO and ONGOING offers.

 

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

Do I qualify?